INM

Mentari Therapeutics Inc

15.56

Nov 06 • 3:59 PM ET +2.35 (17.79%)

15.25

Aftermarket • 7:21 PM ET -0.31 (-1.99%)

Healthcare Drug Manufacturers - Specialty & Generic Canada Nano NASD

Nov 06, 4:10 PMInMed completes merger with Mentari Therapeutics, secures approximately $490 million in financing, to trade on Nasdaq as MTRI

Peers: IXHL CRDL OPTH SUPN ARTL BIVI AXSM AVXL TNXP EYPT

Scroll to Statements

Index	-
Market Cap	8.55M
Enterprise Value	7.42M
Income	-13.60M
Sales	0.82M
Book/sh	-0.22
Cash/sh	2.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Nov 17, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	10.43
P/B	-
P/C	7.57
P/FCF	-
EV/EBITDA	-
EV/Sales	9.05
Quick Ratio	0.50
Current Ratio	0.50
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-3.11
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	63.64% 66.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	55.05%
Sales Y/Y TTM	-82.91%
EPS Q/Q	2.43%
Sales Q/Q	-100.00%
Earnings	Sep 09 AMC
EPS/Sales Surpr.	- -

Insider Own	15.57%
Insider Trans	-
Inst Own	36.84%
Inst Trans	103.10%
ROA	-158.97%
ROE	-224.38%
ROIC	-
Gross Margin	-71.90%
Oper. Margin	-1238.62%
Profit Margin	-1657.72%
SMA20	5.75%
SMA50	11.51%
SMA200	28.13%
Trades

Shs Outstand	5.49M
Shs Float	4.64M
Short Float	0.01%
Short Ratio	0.09
Short Interest	0.00M
52W High	23.30 -33.22%
52W Low	5.75 170.61%
Volatility	16.31% 8.31%
ATR (14)	1.48
RSI (14)	53.95
Beta	1.02
Rel Volume	3.69
Avg Volume	7.39K
Volume	27,314

Perf Week	-2.75%
Perf Month	16.99%
Perf Quarter	10.35%
Perf Half Y	139.38%
Perf YTD	46.79%
Perf Year	-8.74%
Perf 3Y	-81.86%
Perf 5Y	-99.79%
Perf 10Y	-99.92%
Recom	1.00
Target Price	468.78
Prev Close	13.21
Price	15.56
Change %	17.79%

Nov-06-26 04:05PM	InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics (PR Newswire) +17.79%
Nov-05-26 04:01PM	InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI" (Newsfile Corp.) -24.51%
Nov-04-26 04:51PM	InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation (Newsfile)
Nov-03-26 07:30AM	InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update (Newsfile)
Nov-02-26 04:15PM	InMed Announces Share Consolidation in Connection with Proposed Merger (Newsfile Corp.)
08:01PM	Loading…
Oct-26-26 08:01PM	InMed Announces CVR Distribution Record Date in Connection with Proposed Merger (Newsfile Corp.) +10.42%
Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
Sep-18-26 04:45PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance (Newsfile)
Sep-09-26 04:30PM	InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update (Newsfile)
Jul-22-26 07:00AM	Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline (PR Newswire) +7.79%
Jul-06-26 07:15PM	Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? (PR Newswire)
06:20PM	InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 (Newsfile)
Jun-12-26 11:51AM	Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-04-26 05:00PM	InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements (Newsfile)
May-28-26 06:57PM	Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? (PR Newswire) -6.55%
10:37AM	Loading…
May-19-26 10:37AM	InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) (InvestorsHub) +135.05%
08:00AM	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies (PR Newswire)
07:19AM	A migraine drugmaker heads to the public markets through reverse merger (BioPharma Dive)
06:00AM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile Corp.)
May-06-26 06:00PM	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
Apr-27-26 05:30PM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile) -5.03%
Mar-27-26 05:05PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile) -6.22%
Mar-23-26 07:30AM	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program (Newsfile) -6.92%
Mar-18-26 08:00AM	Sidoti Events, LLC's March Small-Cap Virtual Conference (ACCESSWIRE)
Mar-09-26 07:30AM	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial (Newsfile)
Mar-06-26 05:04PM	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline (Newsfile)
Feb-11-26 05:23PM	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -10.09%
Dec-17-25 08:00PM	InMed Announces Results of 2025 Annual General and Special Meeting (Newsfile) -8.75% +7.50%
Dec-12-25 05:30PM	InMed Provides Update on BayMedica Commercial Business (Newsfile) -16.08%
Nov-18-25 07:30AM	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 (Newsfile) -11.52%
04:51PM	Loading…
Nov-06-25 04:51PM	InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -6.16%
Oct-16-25 08:30AM	InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors (Newsfile) -5.45%
Oct-09-25 08:30AM	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors (Newsfile)
Sep-24-25 08:45AM	InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year (TipRanks)
Sep-23-25 08:30AM	InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update (Newsfile) -5.73%
Sep-05-25 01:33PM	InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
Jul-28-25 07:00AM	InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 (Newsfile)
Jun-27-25 07:00AM	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules (Newsfile)
Jun-25-25 08:00AM	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (Newsfile)
Jun-24-25 07:00AM	InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study (Newsfile) +57.96%
Jun-13-25 04:30PM	InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA (Newsfile) -5.95% -6.32%
May-12-25 06:00PM	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +14.91%
Feb-12-25 06:54PM	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile)
Feb-03-25 07:30AM	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Jan-22-25 07:30AM	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds (Newsfile) -20.79%
Jan-21-25 07:30AM	InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study (Newsfile)
Dec-18-24 08:00PM	InMed Announces Results of 2024 Annual General Meeting (Newsfile) -16.18%
Dec-17-24 04:56PM	InMed Enters Into Standby Equity Purchase Agreement (Newsfile)
Nov-19-24 07:30AM	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System (Newsfile)
Nov-14-24 04:45PM	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +9.29% -15.73%
Nov-08-24 04:44PM	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules (Newsfile)
Nov-05-24 08:30AM	InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules (Newsfile) -7.41%
Oct-28-24 07:30AM	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease (Newsfile) +6.63%
Oct-24-24 08:00AM	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease (Newsfile)
Oct-22-24 08:00AM	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board (Newsfile) +10.00%
Sep-30-24 08:00AM	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Sep-20-24 04:30PM	InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date (Newsfile) -12.16%
Aug-21-24 07:30AM	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents (Newsfile)
Aug-20-24 07:30AM	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease (Newsfile) +191.35%
Jul-30-24 08:00AM	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data (Newsfile) -17.59%
Jun-28-24 06:00AM	7 F-Rated Growth Stocks to Avoid Right Now: June 2024 (InvestorPlace)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 05:18PM	InMed to Present at the Emerging Growth Conference (Newsfile)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -15.51%
May-14-24 10:53PM	INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024 (InvestorPlace)
08:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Apr-18-24 08:00AM	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board (Newsfile)
Apr-16-24 08:00AM	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Apr-04-24 08:00AM	InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies (Newsfile)
Mar-20-24 08:30AM	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance (Newsfile)
Feb-13-24 05:41PM	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Jan-18-24 04:41PM	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET (Newsfile)
Jan-16-24 08:00AM	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 (Newsfile)
Dec-19-23 06:03PM	InMed Announces Results of 2023 Annual General Meeting (Newsfile) +5.54%
Nov-29-23 08:00AM	InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration (Newsfile) +21.74%
Nov-14-23 08:04AM	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Nov-02-23 08:00AM	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 (Newsfile)
Oct-26-23 07:15PM	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules (Newsfile) -9.53% -15.93%
Oct-25-23 09:00AM	Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today? (InvestorPlace) -24.18%
Oct-24-23 04:38PM	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules (Newsfile) +70.53%
07:30AM	InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies (Newsfile)
Sep-29-23 01:21PM	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Sep-22-23 06:15PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile)
Sep-07-23 08:30AM	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (Newsfile)
Jul-21-23 07:30AM	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET (Newsfile) +6.05%
Jul-20-23 07:30AM	InMed Provides Update on BayMedica Rare Cannabinoid Business (Newsfile) +5.32%
Jun-22-23 02:28PM	Why Are InMed Pharmaceuticals Stock Trading Lower Today (Benzinga) -13.57%
07:30AM	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa (Newsfile)
Jun-01-23 07:30AM	InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting (Newsfile)
May-24-23 06:51PM	InMed to Participate in Upcoming Virtual Investor Events (Newsfile)
May-18-23 05:00PM	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET (Newsfile) +20.87%
May-15-23 12:33PM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Mar-28-23 07:30AM	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (Newsfile) -9.45%
Mar-13-23 07:30AM	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions (Newsfile) +7.62%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on March 8 Register Now (GlobeNewswire)
Mar-06-23 06:00PM	InMed to Participate in Upcoming Investor Events (Newsfile) +9.82%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Oct 23 '26	Buy	1.32	4	5	956,584	Oct 27 02:13 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 19 '26	Buy	1.32	1,086	1,434	956,580	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 16 '26	Buy	1.32	1	1	955,494	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 14 '26	Buy	1.33	8,021	10,668	954,509	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '26	Buy	1.32	984	1,301	955,493	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 13 '26	Buy	1.33	564	750	946,488	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 06 '26	Buy	1.33	5,601	7,436	940,622	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 07 '26	Buy	1.33	3,046	4,051	943,668	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 08 '26	Buy	1.33	2,256	2,997	945,924	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 05 '26	Buy	1.33	18,182	24,182	935,021	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 01 '26	Buy	1.33	16,431	21,850	908,532	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 02 '26	Buy	1.33	8,307	11,048	916,839	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 15 '26	Buy	1.30	54,256	70,446	883,761	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 14 '26	Buy	1.29	28,505	36,880	829,505	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 16 '26	Buy	1.29	8,340	10,750	892,101	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 15 '26	Buy	1.55	1,000	1,555	801,000	Jul 17 07:29 PM
Vivo Opportunity, LLC	10% Owner	Jul 15 '26	Buy	1.55	15,150	23,482	743,038	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 14 '26	Buy	1.55	5,375	8,331	729,277	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 16 '26	Buy	1.55	21	33	743,057	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 01 '26	Buy	1.55	4,344	6,733	722,935	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jul 02 '26	Buy	1.55	1,607	2,491	724,395	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jun 30 '26	Buy	1.54	600	924	718,989	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	May 20 '26	Buy	1.56	56,210	87,688	543,129	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 05 '26	Buy	1.57	55,011	86,367	688,926	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 21 '26	Buy	1.69	34,000	57,460	574,011	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 08 '26	Buy	1.52	32,500	49,400	718,444	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 02 '26	Buy	1.52	22,848	34,729	625,766	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 29 '26	Buy	1.57	17,796	27,940	590,175	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 01 '26	Buy	1.55	16,336	25,321	605,013	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 03 '26	Buy	1.55	7,783	12,064	632,835	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 04 '26	Buy	1.57	6,743	10,587	638,960	Jun 10 09:14 PM
ADAR1 Capital Management, LLC	10% Owner	May 19 '26	Buy	1.54	468,551	721,548	800,000	May 21 05:08 PM

InMed Pharmaceuticals, Inc. is a pharmaceutical drug development company, which engages in developing small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

M.I.B.Mr. Eric A. Adams B.S. Chem.

CFO & Corporate SecretaryMs. N. Netta Jagpal

Chief Operating OfficerMr. Michael Woudenberg P.Eng.

Senior Vice President of Preclinical Research & DevelopmentDr. Eric Chih-Hsien Hsu Ph.D.

Ph.D.Dr. Sazzad Hossain M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INM

Mentari Therapeutics Inc

Upgrade your Finviz experience